# VivoSim Labs, Inc. (VIVS) · Edgar & Edgarette company card

> VivoSim Labs (VIVS) saw revenue fall 9.0% in FY2026 to $0 million, operating margin -8769% against a -15.8% median for biological products, (no diagnostic substances), equity -14.9% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1497253 · fiscal year ended 2026-03-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/VIVS) · [JSON](https://www.pops4.com/boards/company/VIVS.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $131,000 |
| Revenue growth, 1 year | -9.0% |
| Revenue growth per year | -45.6% |
| Operating margin | -8768.7% (prior year -8761.1%) |
| Net margin | -10567.2% |
| Operating cash flow | −$11M |
| Capital spending | $0 |
| Free cash flow | −$11M |
| Cash | $5M |
| Long-term debt | — |
| Total assets | $7M |
| Total equity | −$1M |
| Equity ÷ assets | -14.9% |
| Return on equity | — |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -164.3 (distress zone)
- Piotroski F: 4 of 9 (middling)
- Beneish M: -4.71 (below the −1.78 line)
- Health Harbor boat: Rotting at the dock · four or more warning signs · filed late annual report notice in the last 12 months; liabilities exceed assets (often from years of share buybacks, not always distress); operating cash flow was negative (-$10.8M in FY2026); operating loss: a margin of -8768.7% in FY2026; revenue is hard to predict: its 80% range is ±84%

## Edgarette's reading

Exposure: revenue $131K (FY2026). Experience: revenue down 9.0% on the year, down 45.6% a year over 4 years; operating margin -8768.7%, down from -8761.1%. Soundness: equity -14.9% of assets (liabilities exceed assets). Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $31K and $354K next year (method v4.1: its own 4-year record of growth weighed at 50% against under $50M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $26K to $421K. A statistical range, not company guidance. Against peers (31 filers, $50M+ revenue, biological products, (no diagnostic substances)): operating margin -8768.7% against a -15.8% median; growth -9.0% against 21.4%.

Range logged 2026-10-07, receipt 22bf6f269124c8c2, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item NT 10-K Late annual report notice: 1, latest 2026-06-29 ([filing](https://www.sec.gov/Archives/edgar/data/1497253/000119312526288413/0001193125-26-288413-index.htm))
- Item 3.01 Exchange listing notice or transfer: 2, latest 2026-08-21 ([filing](https://www.sec.gov/Archives/edgar/data/1497253/000119312526361085/0001193125-26-361085-index.htm))
- Item 5.02 Director or officer change: 1, latest 2026-10-06 ([filing](https://www.sec.gov/Archives/edgar/data/1497253/000119312526415542/0001193125-26-415542-index.htm))

## Recent filings

- 10-Q · filed 2026-11-12 · [filing](https://www.sec.gov/Archives/edgar/data/1497253/000119312526458330/0001193125-26-458330-index.htm)
- 8-K · filed 2026-10-16 · 1.01 Entry into a Material Definitive Agreement; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1497253/000119312526424061/0001193125-26-424061-index.htm)
- 8-K · filed 2026-10-06 · 5.02 Departure or Election of Directors; Appointment of Officers; 5.07 Submission of Matters to a Vote of Security Holders; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1497253/000119312526415542/0001193125-26-415542-index.htm)
- 8-K · filed 2026-08-21 · 3.01 Notice of Delisting or Failure to Satisfy a Listing Rule; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1497253/000119312526361085/0001193125-26-361085-index.htm)
- DEF 14A · filed 2026-08-21 · [filing](https://www.sec.gov/Archives/edgar/data/1497253/000119312526361066/0001193125-26-361066-index.htm)
- 10-Q · filed 2026-08-12 · [filing](https://www.sec.gov/Archives/edgar/data/1497253/000119312526346820/0001193125-26-346820-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001497253.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1497253

## Cite

POPS4, Edgar & Edgarette: VivoSim Labs, Inc. (VIVS) company card, from the company's own SEC filings, accessed 2026-11-21, https://www.pops4.com/boards/company/VIVS. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.

